“The PRO / eCOA Congress is the leading European event for obtaining pragmatic information on the clinical science, regulatory and innovative technologies used to collect patient safety and efficacy data during clinical development,”
Philadelphia (PRWEB) September 03, 2015
ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions today announced the complete faculty of its 8th Annual European PRO and eCOA Congress in Lisbon, Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry experts will lead interactive discussions on effectively implementing Patient Reported Outcomes (PRO) and electronic Clinical Outcome Assessments (eCOA) strategies for endpoint data collection in clinical development.
Congress registration can be found here.
The European Congress faculty is comprised of international biopharmaceutical, regulatory, and industry experts, including:
- Lisbeth Bregnhoj, Medicines Inspector of the Danish Health and Medicines Authority will present "eSource: Comparisons of Global Regulatory Perspectives and Guidances”
- Bryan McDowell, Global Program Team Director, Novartis will present “Innovation in Clinical Trials and the Patient Experience”
- Eva-Cornelia Ticinelli, Clinical Research Manager LETI Pharma GmbH will present “Practical Experiences with BYOD in a Phase 3 Trial”
“The PRO / eCOA Congress is the leading European event for obtaining pragmatic information on the clinical science, regulatory and innovative technologies used to collect patient safety and efficacy data during clinical development,” said Dr. Susan M. Dallabrida, Vice President of Clinical Science and Consulting, ERT and Congress speaker. “We’re very excited for Ms. Bregnjhoj to bring her regulatory perspective to the discussion – and for Congress attendees to have the opportunity to network with so many industry experts who can address their questions on the important role patient data has in meeting their clinical development objectives.”
Additional information on Congress faculty and agenda can be found at https://www.ert.com/2015-pro-and-ecoa-congress/.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Switzerland, Japan and Germany. Join ERT on Facebook, LinkedIn, Twitter, and YouTube.